The United Laboratories International Holdings Limited (HKG: 3933)

Market Cap	21.11B
Revenue (ttm)	15.05B
Net Income (ttm)	3.12B
Shares Out	1.82B
EPS (ttm)	1.72
PE Ratio	6.76
Forward PE	6.49
Dividend	0.62 (5.53%)
Ex-Dividend Date	Sep 19, 2024

Volume	3,745,800
Average Volume	4,044,114
Open	11.12
Previous Close	11.12
Day's Range	11.12 - 11.66
52-Week Range	6.60 - 12.58
Beta	0.00
RSI	54.49
Earnings Date	Mar 26, 2025

About The United Laboratories International Holdings

The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, amoxicillin...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 15,000
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3933

Financial Performance

In 2023, The United Laboratories International Holdings's revenue was 13.74 billion, an increase of 21.22% compared to the previous year's 11.33 billion. Earnings were 2.70 billion, an increase of 70.85%.

Financial numbers in CNY